ADHD care doesn’t stop at diagnosis, and how should clinicians effectively measure progress? See how effective communication and continuity of care lead to better long-term outcomes for patients and clinics: https://bit.ly/4lUorvz

When you leverage tech-forward care, you empower your patient population. This is a great example of how a virtual pathway empowered a patient to become an expert in his ADHD journey. Read the complete story: https://bit.ly/4nHIUGc

Great news! The NSW Government has expanded ADHD care, allowing trained GPs to prescribe and renew medications — reducing wait times, easing specialist backlogs, and making treatment more affordable for families across the state. Learn more: https://lnkd.in/gVKaMxjy

Two speakers with two big topics you can’t miss at #MM2025AdPha: The Aged Care Onsite Pharmacist (ACOP) care model and Management of ADHD in adults Michael Bonner unpacks the Aged Care Onsite Pharmacist (ACOP) care model where he shares the tools, skills and strategies that empower pharmacists to collaborate across the aged care journey and improve patient care. ➡️ Learn more about Michael’s session https://buff.ly/gYHjn6s Katarzyna Tognarini explores the growing challenge of Adult ADHD, bringing the new Australian Evidence-Based Clinical Guideline to life. Gain practical insights to navigate complexities and better support adult patients. ➡️ Learn more about Kate’s session https://buff.ly/pU4MyIf #MM2025AdPha is attracting leading voices on the most pressing issues in pharmacy. Don’t miss out on the conversations shaping patient care. Explore the full program today https://buff.ly/5grwgTD

GPs in New South Wales can now take part in major reforms that will make it easier for people with ADHD to access care. https://lnkd.in/d92rC-sn

In England, autism and ADHD assessment wait times are staggering - 30 to 44 weeks, compared to the NICE‑recommended 13 weeks. And behind each waitlist is a person struggling. iaptus is helping services cut through the backlog, with capabilities that enable: 📋 Streamlined referrals & triage 📊 Real-time caseload visibility 🔄 Customisable workflows 📈 Outcome tracking that supports funding 🧩 Flexible pathways that adapt to need Health, education, and care must work together, but digital tools can make a big impact. Let’s help neurodivergent patients access timely support.💚 👉 https://ow.ly/Nbrs50WSZPa #Neurodiversity #WaitingLists #MentalHealth

It’s concise. It’s clear. And it opens the door for more meaningful discussions with your patients about treatment and care. The Total Symptom Score is a summary of your patient's performance and can be an effective means of ADHD psychoeducation. See how one tool helps you explain results in a way patients (and parents) actually understand: https://bit.ly/45Mp3O2 Thank you Corina Weir (PhD, CPsychol)

Experts break down the diagnostic thresholds and explore why inattentive presentations, especially in girls and high-achieving students, are often overlooked. Learn more about accurate identification and evolving insights into ADHD with this Clinical Case Collective custom video series: https://hubs.li/Q03B6gR00

When someone struggles with focus or impulsivity, it’s easy to assume it’s “just life.” But with tools like QbCheck, we can measure it more clearly. QbCheck is a clinically validated tool used in ADHD assessments to track attention, movement, and impulsivity in real-time. It’s recommended by NICE for children and young people aged 6–17, but also widely used in adult assessments to provide supportive, objective data. 🔍 Why it matters: QbCheck helps build a more complete clinical picture, adding evidence to what you’re experiencing, and helping rule out or explore other factors. It’s not a diagnostic tool on its own. But in expert hands, it strengthens the process and supports clearer outcomes. #adhdassessment #qbcheck #neurodiversitysupport

Writing this blog was one of the most difficult stances I’ve taken on. Not because the data wasn’t there—it’s all right in front of us. The hardest part was confronting how deeply normalized this issue has become. We’ve accepted a school system where kids line up at noon for controlled substances… while safer, gentler alternatives remain stigmatized or banned outright. If a child has an asthma inhaler at school, no one blinks. If a child takes a stimulant or benzo, it’s quietly normalized. But if a child uses carefully dosed cannabis for seizures or autism, it’s forbidden. What does that say about our values—or our blind spots? My hope is that this piece sparks a conversation that goes beyond medicine, into the realms of culture, ethics, and the future of care. https://lnkd.in/eZ8hvJr8